Angiopoietins in Diabetic Retinopathy: Current Understanding and Therapeutic Potential.
Journal of diabetes research
Hindawi Publishing Corporation
MetadataShow full item record
Whitehead, M., Osborne, A., Widdowson, P. S., Yu Wai Man, P., & Martin, K. (2019). Angiopoietins in Diabetic Retinopathy: Current Understanding and Therapeutic Potential.. Journal of diabetes research, 2019 5140521. https://doi.org/10.1155/2019/5140521
Diabetic retinopathy (DR) is the commonest cause of blindness in the working-age population of the developed world. The molecular pathophysiology of DR is complex and a complete spatiotemporal model of the disease is still being elucidated. Recently, a role for angiopoietin (Ang) proteins in the pathophysiology of DR has been proposed by several research groups, and several aspects of Ang signalling are being explored as novel therapeutic strategies. Here we review the role of the Ang proteins in two important forms of DR, diabetic macular oedema and proliferative diabetic retinopathy. The function of the Ang proteins in regulating blood vessel permeability and neovascularisation is discussed and we also evaluate recent preclinical and clinical studies highlighting the potential benefits of modulating Ang signalling as a treatment for DR.
Animals, Humans, Diabetic Retinopathy, Diabetes Mellitus, Diabetes Complications, Angiopoietins, Hypoglycemic Agents, Signal Transduction, Macular Edema
MW and PYWM are funded by Medical Research Council (UK) grants. MW, PYWM and AO 386 receive support from The Novo Nordisk UK Research Foundation, the Cambridge Eye Trust and 387 the Jukes Glaucoma Research Fund. AO, PYWM and KRM also hold Fight for Sight (UK) awards. 388 PYWM is also supported by a Clinician Scientist Fellowship Award (G1002570), the Isaac Newton 389 Trust, the UK National Institute of Health Research (NIHR) as part of the Rare Diseases 390 Translational Research Collaboration, and the NIHR Biomedical Research Centre based at 391 Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology. Research in 392 the laboratory is supported by core funding from Wellcome and MRC to the Wellcome-MRC 393 Cambridge Stem Cell Institute.
Cambridge Eye Trust (unknown)
Embargo Lift Date
External DOI: https://doi.org/10.1155/2019/5140521
This record's URL: https://www.repository.cam.ac.uk/handle/1810/295039
All rights reserved